Venous limb gangrene and fatal hemorrhage: Adverse consequences of hit "overdiagnosis" in a patient with antiphospholipid syndrome

American Journal of Hematology

Volumn 86, Issue 2, 2011, Pages 188-191

  Smythe, Maureen A ^a,b   Warkentin, Theodore E ^c   Woodhouse, Amy L ^d   Zakalik, Dana ^a  

^a BEAUMONT HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d WellStar Kennestone Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ARGATROBAN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; FONDAPARINUX; HEMOGLOBIN; UREA; WARFARIN;

ADULT; AFRICAN AMERICAN; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; CASE REPORT; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DOPPLER ECHOGRAPHY; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; GANGRENE; HEMOGLOBIN BLOOD LEVEL; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LABORATORY TEST; LIMB; PAIN; PRIORITY JOURNAL; SWELLING; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL; VENOUS LIMB GANGRENE;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; DIAGNOSTIC ERRORS; DRUG MONITORING; FATAL OUTCOME; FEMALE; GANGRENE; HEMORRHAGE; HUMANS; LUNG DISEASES; MIDDLE AGED; PIPECOLIC ACIDS; THROMBOCYTOPENIA; UPPER EXTREMITY; VASCULAR DISEASES; WARFARIN;

EID: 78851468851     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21916     Document Type: Article

References (25)

1. Package insert, PF4 Enhanced®. GTI, Waukesha, WI, January 13, 2005.
2. Warkentin TE. Antiphospholipid and anti-PF4 antibodies: An association affecting anti-PF4/heparin assay analysis. J Thromb Haemost 2009; 7: 1067-1069.
3. Whitlatch NL, Perry SL, Ortel PT. Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 2008; 100: 678-684.
4. Warkentin TE. Confirmatory procedure and other maneuvers to assess pathogenicity of platelet factor 4 (PF4)-dependent antibodies-distinguishing "signal" from "noise". Thromb Haemost 2008; 100: 523-524.
5. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
6. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4: 759-765.
7. Martin-Toutain I, Piette JC, Diemert MC, et al. High prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia. Lupus 2007; 16: 79-83.
8. Pauzner P, Greinacher A, Selleng K, et al. False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost 2009; 7: 1070-1074.
9. Sikara MP, Routsias JG, Samiotaki M, et al β2 Glycoprotein I (β2GPI) binds platelet factor 4 (PF4): Implications for the pathogenesis of antiphospholipid syndrome. Blood 2010; 115: 713-723.
10. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356: 2653-2654.
11. Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight-heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 2008; 99: 779-781.
12. Salem M, Elrefai S, Shrit MA, et al. Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia complicated by arterial thrombotic stroke. Thromb Haemost 2010; 104: 1071-1072.
13. Warkentin TE. Agents for the treatment of heparin-induced thrombocytopenia. Hematol Oncol Clin N Am 2010; 24: 755-775.
14. Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost 2008; 99: 819-829.
15. Kearon C, Johnston M, Moffat K, et al. Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Int Med 1998; 158: 1140-1143.
16. Warkentin TE. Should vitamin K be administered when HIT is diagnosed after administration of coumarin? J Thromb Heamost 2006; 4: 894-896.
17. Smythe MA, Warkentin TE, Stephens JC, et al. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin induced thrombocytopenia. Am J Hematol 2002; 71: 50-52.
18. Warkentin TE. Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis. Ann Int Med 2001; 135: 589-593.
19. Asherson RA. The catastrophic antiphospholipid (Asherson's) syndrome. Autoimmunity Rev 2006; 6: 64-67.
20. Walenga JM, Hoppensteadt DA. Monitoring of new antithrombotic drugs. Semin Thromb Hemost 2004; 39: 683-695.
21. Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost 2007; 98: 234-242.
22. Godier A, Mesmay MD, Be'canne X, et al. Argatroban and renal replacement therapy in a morbidly obese patient with heparin-induced thrombocytopenia: A case report. Thromb Res 2010; 126: e141-e143.
23. Perry SL, O'Shea SI, Ortel TL. Management of lepirudin therapy for a patient with antiphospholipid antibody syndrome using the whole blood ecarin clotting time and activated partial thromboplastin time. Blood Coagul Fibrinolysis 2003; 14: 601-604.
24. GlaxoSmithKline. Argatroban prescribing information. NC: Research Triangle Park; 2008.
25. Santiago-Casas Y, Vilá LM. Pulmonary hemorrhage in patients with systemic lupus erythematosus. Curr Resp Med Rev 2009; 5: 49-54.